You are here: Home » PBL Technologies » Health and Medicine » Enteric Delivery of Biologics
09.490 - Enteric Delivery of Biologics
Patent Reference: International Patent Publication No. WO2006/079790.
Simon Carding, Institute of Food Research (Norwich, UK)
Mark Farrar, Leeds University (UK)
The diet-inducible expression of therapeutic proteins from a human commensal bacterium provides for an effective therapeutic intervention for immune-mediated iseases
• The gut-commensal bacterium Bacteroides ovatus is part of the natural human enteric microflora, and has been shown to provide beneficial effects when administered as a probiotic.
• Secretion of therapeutic proteins occurs only in response to the presence of xylan, so delivery is tuneable to disease severity.
• Obligate anaerobiosis and antibiotic sensitivity provides greater biosafety
• Exemplification in an animal model of acute colitis, using TGFâ or KGF as the therapeutic agent.
• Therapeutic is produced locally at the site of damage, and is not systemically disseminated, leading to lower risk of side effects.
1. Baumgart, DB and SR. Carding. 2007. The Lancet. 369:1627-1638
2. Hamady, ZR et al. 2008. Microbiology. 154:3165-3174
3. Farrar, M.D. et al. 2005. J. Appl. Microbiol. 98:1191-1197
4. Hamady, ZR et al. 2010. Gut. 59:461-9
Contact: Dr Martin Stocks
Download non-confidential summary (PDF): Click here